CAR-T Anti-FAP Fibroblasts
Idiopathic Pulmonary Fibrosis · Direct clearance of FAP+ activated myofibroblasts via chimeric antigen receptor T cells
Mechanism
Direct clearance of FAP+ activated myofibroblasts via chimeric antigen receptor T cells
Development stage
Preclinical
Evidence level
Level 2 (Preclinical)
Developer
Penn / Multiple
Overview
Nature 2022: FAP-CAR-T cleared cardiac fibrosis in mice. Lung fibrosis has same FAP+ myofibroblast target. Cross-reactive FAP scFv-based CAR-T evaluated for efficacy/safety 2024. Cancer crossover: same CAR design eliminates cancer-associated fibroblasts.
Explore related
Medical disclaimer. This page summarizes research about CAR-T Anti-FAP Fibroblasts for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.